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Abstract
Among the known biomarkers, chemokines, secreted by activated macrophages and T cells, attract groups of immune cells
to the site of infection and may determine the clinical outcome. Association studies of CCL-2/MCP-1 -2518 A/G functional
SNP linked to high and low phenotypes with tuberculosis disease susceptibility have shown conflicting results in
tuberculosis. Some of these differences could be due the variability of latent infection and recent exposure in the control
groups. We have therefore carried out a detailed analysis of CCL-2 genotype SNP -2518 (A/G transition) with plasma CCL-2
levels and related these levels to tuberculin skin test positivity in asymptomatic community controls with no known
exposure to tuberculosis and in recently exposed household contacts of pulmonary tuberculosis patients. TST positivity was
linked to higher concentrations of plasma CCL2 (Mann Whitney U test; p=0.004) and was more marked when the G allele
was present in TST+ asymptomatic controls (A/G; p=0.01). Recent exposure also had a significant effect on CCL-2 levels and
was linked to the G allele (p=0.007). Therefore association studies for susceptibility or protection from disease should take
into consideration the PPD status as well as recent exposure of the controls group used for comparison. Our results also
suggest a role for CCL-2 in maintaining the integrity of granuloma in asymptomatic individuals with latent infection in high
TB burden settings. Therefore additional studies into the role of CCL-2 in disease reactivation and progression are
warranted.
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Introduction
One third of the world’ population is latently infected with M.
tuberculosis and forms the largest pool contributing to new cases.
Among the 20 high TB burden countries, Pakistan ranks 8
th
despite .95% coverage with BCG vaccination at birth [WHO/
UNICEF, 2009]. In Pakistan, latent infection as assessed by
tuberculin skin tests (TST) in the community has been reported to
be as high as 40–50% [1]and even higher(70–80%) in the exposed
household contacts [2]. The highest number of TB cases is
contributed by this pool of latently infected individuals. It is
therefore important to understand the molecular determinants
associated with latent infections and active disease in tuberculosis
in this high TB endemic setting.
TST was introduced a century ago and is the oldest test for
detection of cell mediated immunity in tuberculosis and is therefore
considered to be a marker of latent infection in asymptomatic
individuals. TST positivity can be affected by conditions which
compromise the immune system in the host such as poor nutrition,
advanced age and infections such as HIV and diabetes. Additional
surrogate immune markers associated with latent infections or
individuals at risk of developing latent infection would be of
tremendous help to National TB programs.
Among the immune markers, chemokines play an important role
in the initial stages of infection by recruiting leukocytes to the
infected or inflamed sites in the peripheral tissues [3]. Chemokines
participate in the growth, differentiation and activation of
leukocytes and stimulate various effector functions such as
chemotaxis, integrin activation, superoxide radical production and
granule enzyme release. Chemokines, therefore, serve as critical
components of basal leukocyte trafficking essential for immune
system architecture, development and immune surveillance [3].
One such C-C chemokine CCL-2, is produced by activated T
cells and macrophages and exclusively recruits monocytes and T
cells to the site of infection in mycobacterial diseases. CCL-2 is the
most potent activator of macrophages where it derives its earlier
name of macrophage chemoattractant protein-1 (MCP-1) [4].
Since mycobacteria reside and multiply within the macrophages,
levels of macrophage recruiting chemokines may play a crucial
role in effective recruitment of and activation of appropriate
effector T cells at the site of infection. CCL-2 predominantly
recruits memory T cells to the site of infection and therefore may
play an important role in maintaining the architecture of
granuloma in latent infection.
A single nucleotide polymorphism (-2518 A/G) in the CCL-2/
MCP-1 gene, controls the level of CCL-2 protein [5]. Cells with
the homozygous AA genotype secrete significantly less CCL-2
than do cells with either AG or GG genotype [5,6]. CCL-2
(-2518GRA) SNP has shown variable association of G
hi allele with
either susceptibility to TB [6,7] or no association with TB [8–10],
(see Table S1). Some of these differences could be due to
differences in TST status of the controls used for comparison with
TB groups which included blood donors [8], community controls
with unknown TST status [6,11–13] [6] or TST positive controls
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as in the prevalence of latent infection in populations and therefore
it is difficult to compare controls between studies. Only one report
studied the association of plasma levels with CCL-2 -2518 SNPs
and found no difference in the CCL-2 plasma levels in healthy
tuberculin reactors and non reactors. [6]. However, genotype
analysis in relation to CCL-2 in tuberculin reactors and non
reactors was not done.
I nt h ec u r r e n ts t u d yw eh a v ec a r r i e do u tad e t a i l e da n a l y s i so f
CCL-2 genotype SNP -2518 (A/G transition) with plasma CCL-2
levels in asymptomatic controls with no known exposure to
tuberculosis, and in recently exposed household contacts of
pulmonary tuberculosis patients and related these levels to tuberculin
skin test positivity. Plasma CCL-2 levels showed no relationship with
CCL-2 -2518 SNP in the asymptomatic controls. However, TST
positivity was associated with higher concentrations of plasma CCL-2
and was more marked when the Ga l l e l ew a sp r e s e n ti nb o t h
household contacts and the community control groups. Therefore
CCL-2 genotype and phenotype may play an important role in both
establishment of latency and maintenance of granuloma.
Materials and Methods
Ethical statement
A name de-linked DNA bank and paired plasma samples were
available on exposed household contacts (HC) and community
based healthy controls (EC) in the department of Pathology and
Microbiology through previously funded projects. Ethical approval
by The Aga Khan University Ethical Review Committee was
obtained for the project (1451-Path-ERC-2010).
Study groups
This study group consisted of BCG vaccinated, asymptomatic
healthy controls (N=196). Detailed information was available on each
household contact with respect to previous exposure, anti-tuberculous
treatment (ATT), immune modifying treatment and co-morbidities
which may affect immune responses such as diabetes, HIV etc.
Household contacts (N=110) of tuberculosispatients were living with a
pulmonary tuberculosis patients pretreatment for a minimum of 3
months. Endemic community controls (EC=86) had no recent history
of exposure or previous history of tuberculosis treatment.
Tuberculin skin tests
Tuberculin skin tests (TST) were carried out by injecting 5 TU
intra-cutaneously in the volar surface of the arm (Tubersol
tm,
purchased from Sanofi Pasteur Limited, Ontario Canada). A
single tester administered and read the indurations after 48 hours
using a caliper. A diameter $10 mm was considered positive [15].
Written consent was obtained from each participant.
Collection of plasma
Five ml of blood was collected by venipuncture from each donor
and mixed with sodium heparin (20 U/ml; Leo pharmaceutical,
Ballerup, Denmark) in 15 ml of plastic centrifuge tubes. Red blood
cells were allowed to settle and plasma from whole blood was
collected and stored as small aliquots at 280uC until use.
Assessment of CCL-2 levels in plasma
Chemokine levels in plasma were estimated using Flow
Cytometric Bead Array (CBA) from BD Biosciences Ca, USA.
Thisequipment allows detectionofseveral cytokinesorchemokines,
simultaneously in small volumes of samples and is kit based. The
principle of CBA is the use of beads with discrete fluorescence
intensities. Each bead with a single fluorescent intensity is coated
with a different monoclonal capture antibody and serves to capture
the soluble analyte present in plasma, serum, stimulated culture
supernatants, cell lysate or other body fluids. A reporter antibody
that is attached to fluorescence molecule of phycoerythrin [PE] is
used to quantify the captured analyte of interest. Kits are available
for a combination of chemokines and cytokines. Chemokine Kit
(Human chemokine kit) was purchased from BD biosciences. This
kit detects 5 related chemokines (CXCL-8/IL-8; CCL5/RANTES;
CXCL-9/MIG; CCL-2; CXCL10/IP10). Plasma was diluted 1:5
and in-filter plate assay was used. The sensitivity was in the range of
2.5–5.0 pg/ml as given by the manufacturer.
Molecular analysis
DNA Extraction. Five ml blood was collected in ACD tubes
(VWR Scientific, West Chester, PA, USA). Genomic DNA was
extracted from whole blood as described in detail previously [16].
Promega Wizard Genomic DNA Purification Kit (Promega
Corporation Madison, WI, USA) was used according to the
manufacturer’s instructions. DNA was quantified by spectro-
photometer and stored at 235uC until further analyses.
Detection of CCL-2 SNPS. CCL-2 genotype SNPs (-2518)
analyses were carried out using conventional PCR followed by
sequencing of the PCR products. The primers were designed using
web based software ‘‘BatchPrimer3’’. Primers were purchased
from MWG-Biotech AG, (Ebersberg, Germany) (CCL-2 Forward:
TCT GGG AAC TTC CAA AGC TG & CCL-2 Reverse: GCC
ACA ATC CAG AGA AGG AG). After completion of 25 PCR
cycles, 5 ml of each PCR product was mixed with 1 mlo f6 6
bromophenol blue loading dye. Products with dye were loaded on
2% agarose gel prepared in Tris-acetate EDTA (TAE) buffer with
10 mg/ml ethidium bromide. 100 base pair molecular marker was
also loaded in one of the wells for reference. These products were
then run for 45 minutes at 120 volts in electrophoretic tank
containing TAE buffer. Product bands were visualized on a UV-
transilluminator and pictures were taken of the visible bands (Figure
S1).PCR products (25–30 ml) were sent to Macrogen (Macrogen Inc,
Seoul, Korea) for sequencing. Sequencing results were analyzed by
multiple alignments of the sequences using software ‘‘Clustal W
version 1.83’’. CCL2 genotypes (-2518) were calculated by referring
chromatograms of the sequencing results provided by Macrogen.
Statistical analysis
Computer software SPSS version16.0 and Epi Info 2000
applications were used to carry out statistical analyses. Kruskall
–Wallis was applied to test for differences among related groups.
Mann-Whitney U test was applied when N was ,20 in any group
and student t test when the N was .20 to determine significant
differences between groups. For categorical data, Chi square test
was applied. Allelic Frequencies were compared between groups
by Pearson chi-squared tests or Fisher’s exact tests when analyzing
allelic frequencies lower than five to determine statistical
significance differences between groups. Odds ratios (OR) with
respective confidence intervals (95% CI) for disease susceptibly
were also calculated. Linear-by-linear test were used to determine
the significance (corrected p values) of genotypes between healthy
controls and disease groups. Values of p,0.05 were considered
significant for both Pearson and linear-by-linear x
2 test.
Results
Characteristics of the study groups and subgroups
Asymptomatic donors with no history of tuberculosis treatment
(Tuberculosis Not Affected individuals; TBNA=196) and where
CCL2 genotype SNPs analysis was available, were included in the
CCL2/MCP1 Is Elevated in Latent Tuberculosis
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BCG vaccinated endemic controls (EC=86) with no history of
recent exposure to active tuberculosis patients and 2) recently
exposed household contacts (HC=110) living with an index case of
open pulmonary tuberculosis for at least 3 months [17] and were
asymptomatic at the time of intake. There was no difference in age
or gender among the two groups (chi test, P.0.1) (Table 1). The
availability of TST status in EC and HC is also given in Table 1.
Positive TST($10 mmindurations)inthe HCgroup (75%)was1.5
-fold higher compared to the EC group (46%). We first addressed
theissue if therewasan associationofCCL-2 -2518 SNPwith CCL-
2 plasma levels in the asymptomatic group. Paired CCL2 genotype
and phenotype was available in a subset of TBNA (N=142).
No association of Plasma CCL-2 levels with CCL-2
genotype in TBNA
Figure 1 shows the effect of CCL-2 -2518 SNPS on plasma
CCL-2 levels in asymptomatic group (TBNA=142). CCL-2
plasma levels were similar in donors irrespective of the genotypes
(Kruskall-Wallis p=0.454).
Higher plasma CCL-2 levels are significantly associated
with latency
Plasma CCL2 levels were available in 157 TBNA donors. We
analyzed CCL-2 plasma levels in groups stratified on the basis of 1)
remote (EC=65) or recent (HC=92) infection and 2) TST status
in these groups (Table 2). TBNA showed the most significant
difference in the mean plasma CCL-2 levels when groups were
stratified on the basis of TST status (p=0.004). The effect of
recent infection on CCL2 plasma levels compared to remote
infection was only marginal (p=0.052) and when these two groups
were restricted by TST positivity there was no significant
difference in CCL-2 levels in the two groups. These results suggest
that that elevated CCL-2 plasma levels in the HC group may
associated with the higher rate of latent infection (HC 75% Vs EC
46% TST+) rather than recent exposure.
CCL-2 -2518 GG genotype is overrepresented in the
household contacts compared to community controls
We next compared CCL-2 (-2518 SNP) genotypes within each
of these subgroups (Table 3). Genotypes were in Hardy-Weinberg
Equilibrium (HWE) in all groups. Although the highest difference
in plasma CCL-2 levels was observed between TST+ and TST2
TBNA (MWU p=0.004), there was no difference in the genotype
or allele frequency between these two groups. Surprisingly, the
only groups showing significant genotype difference were the HC
group compared to the EC group (x2=8.98; p=0.003) with an
overrepresentation of G allele in the HC group, although the
plasma CCL-2 levels were only marginally different (p=0.052;
Table 2) in these two groups. Since the HC group had much
Table 1. Characteristics of the study group.
Group ID N Age ± SD Sex ratio M/F (ratio) *TST status N positive/N tested (% positive)
TBNA 196 27.91612.58 90/106 (0.85) 117/184 (61%)
EC 86 29.1267.63 33/53 (0.62) 34/74 (46%)
HC 110 26.96615.35 57/53 (1.08) 83/110 (75%)
Note: TBNA= TB not affected:
TBNA Subsets=EC=Community Controls, HC exposed household contacts.
*Cut off for TST positivity $10 mm of indurations.
doi:10.1371/journal.pone.0025803.t001
Figure 1. CCL-2 genotype-phenotype relationship in healthy asymptomatic control groups. PCR and sequencing analyses was carried
out to determine the CCL-2 (SNP -2815) (see Figure S1) and BD FACS array was carried out to determine CCL-2 protein in plasma samples. The
number in each genotype is indicated in the brackets. Kruskall-Wallis (KW) analysis was applied to determine significant differences across groups.
doi:10.1371/journal.pone.0025803.g001
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suggest that the household contacts were at a higher risk of
developing latent infection due to the presence of CCL-2 -2518
GG genotype. We therefore also analyzed the linkage of plasma
CCL-2 with different genotypes in different groups in relation to
TST status.
Genotype-phenotype relationship of CCL-2 -2518 SNPS
in TBNA stratified by TST status
The effect of CCL-2 genotypes on CCL-2 plasma levels was first
examined in TBNA according to their TST status (Figure 2).
TST+ donors with AA genotype showed comparable responses in
both TST+ and TST2 groups. However, there was a significantly
higher level of plasma CCL-2 in the TST+ donors when G allele
was present. Due to a low number of donors with GG genotype in
TST-, there was insufficient numbers to carry out meaningful
statistical analysis but there was a clear overrepresentation of GG
genotype in TST+TBNA compared to TST-TBNA indicating
that donors with G allele may be at a higher risk of developing
latent infection and that this may be dose dependent.
Genotype-phenotype relationship of CCL-2 -2518 SNPS
in HC group compared to EC group
We next compared the effect of CCL-2 genotype in TBNA
stratified either on the basis of exposure (EC=remote Vs
HC=recent) (Figure 3 A) or TST status (Figure 3 B). We have
given results for only AA and AG genotypes as there were
insufficient numbers of donors with GG genotype in the EC group
for meaningful statistical analysis. The differences in CCL-2
plasma levels in the HC and EC groups were much more marked
when G allele was present (p=0.007). This difference became less
marked (p=0.026) when the groups were restricted by TST
positivity (Figure 3B). Again donors with AA genotype showed
comparable responses irrespective of the TST status. These results
therefore show that higher CCL-2 levels are present in latently
infected individual and that the presence of G allele may further
boost CCL-2 plasma levels in household contacts.
Receiver Operator Curves (ROC) analysis between EC and
HC groups
We next analyzed the discriminating power of plasma CCL-2
levels in community controls and household contacts. Receiver
Operator Curves were generated for comparison between different
groups and AUROC and p values are shown in Table 4.A s
expected the CCL-2 showed the best discrimination between EC2
and HC+ groups (AUROC=0.736; p=0.0003) and slightly
less between the EC2 group and the unstratified HC group
(AUROC=0.694; p=0.002). The least discrimination was
observed when the comparison was restricted to TST+ in EC
and HC group again indicating an association of CCL2 levels with
TST positivity.
Discussion
There is a high rate of latency as assessed by TST positivity in
TB endemic setting which is attributed to BCG vaccination,
exposure to environmental mycobacteria or high rate of
transmission within the community. The host immune factors
which influence this high rate of latent infection in an endemic
setting are as yet incompletely understood.
Tuberculin Skin Tests (TST) was 1.5-fold higher in the HC
group compared to the EC group. The higher rate of TST
positivity in household contacts [17] could either be due to recent
exposure or a higher genetic susceptibility for latent infection as all
household contacts were blood relatives of tuberculosis patients. In
TB endemic countries the high rate of TST+ positivity particularly
in the community controls has been attributed to factors other
than recent exposure such as BCG vaccination or exposure to
environmental mycobacteria which may boost T central memory
cells in BCG vaccine’s [18]. Similarly interferon gamma release
Table 2. CCL-2 levels in plasma in relation to infection and
disease in tuberculosis.
Groups (N) N Mean (pg/ml) ±SE p=
TBNA 157 59.8 4.5
TBNA (+) 91 71.6 6.2
TBNA (2) 49 47.4 6.3 0.0040
EC 65 45 9.2
HC 92 70.1 3.7 0.052
EC (+)2 3 6 7 2 1 . 1
HC (+) 68 73.2 4.4 0.3
Note: TBNA=TB not affected:
TBNA Subsets=EC=Community Controls; HC exposed household contacts.
(+)=TST positive (.=10 mm indurations); (2)=TST negative (,10 mm
indurations).
Significance of differences was assessed by applying student t tests (1 tail,
type 3).
A p value of ,0.05 was considered significant.
doi:10.1371/journal.pone.0025803.t002
Table 3. CCL-2 (-2518 G/A) genotype and allele analysis.
CCL-2 –
2518
TBNA
(+) TBNA (2) EC HC EC(+) HC(+)
SNP
Genotype ff f f f f
N 117 67 86 110 34 82
AA 41.88 49.30 45.35 43.64 44.12 41.46
AG 43.59 44.80 51.16 39.03 50 40.2
GG 14.53 15.97 3.49 17.27 5.88 18.29
X
2 2.39 8.98 2.89
Corrected Vs TBNA+ Vs EC Vs EC+
p= .122 0.003 0.089
allele
A 63.675 71.6 70.93 63.18 69.12 62.59
G 36.325 28.4 29.07 36.82 30.88 38.41
X
2 2.42 2.6 1.18
p= .21 .107 .277
OR .69 .7 .72
95% CI 0.44–1.1 0.46–1.08 0.39–1.31
HWE p= .876 .615 .957 .515 .876 .615
Note: TBNA=TB not affected:
TBNA Subsets=EC=Community Controls, HC exposed household contacts.
TST positive=(+); TST negative=(2). TST positivity cut off=$10 mm
indurations.
HWE=Hardy Weinberg Equilibrium. P,0.05 is considered significant.
doi:10.1371/journal.pone.0025803.t003
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controls. TST+ (cut off .=10 mm diameter indurations). The number in each panel is indicated in the boxes. Significant differences were
determined by Mann Whitney U analysis between different genotytpes. A p value ,0.05 was considered significant. Genotypes were unavailable on 2
donors and therefore not included. All other parameters are same as in table 2 and 3.
doi:10.1371/journal.pone.0025803.g002
Figure 3. CCL-2 genotype-phenotype relationship in the presence (TST+) or absence (TST-) of latency in recently exposed
household contacts (Panel A) and healthy community controls (Panel B). The number in each group is indicated in the boxes. Significant
differences were determined by Mann Whitney U analysis between different genotytpes. A p value ,0.05 was considered significant.
doi:10.1371/journal.pone.0025803.g003
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discriminate latent infection from recent exposure and have very
little added value in an endemic setting [19]. Surrogate biomarkers
for latent infection have therefore been an area of intense
investigation which include an array of stimulated cytokines
[20][2]. Less attention has been paid to chemokines which are
considered to be derived from the innate arm and hence less
specific. However, there has been increasing interest in chemo-
kines as markers of infection and disease [21]. Among the
chemokines, CXCL10/IP10, a chemokine induced by IFN- c has
shown promising results as marker of tuberculosis disease in
children [22]. We have also previously reported that among the
several endogenously and exogenously activated chemokines [23–
26] CCL2 is elevated in the more severe form of tuberculosis [23].
Kinetic patterns of chemokine and cytokine profile in M. bovis
BCG induced chemokines from human peripheral blood mono-
nuclear cells show that CCL2 is released early post stimulation
while CXCL10/IP10 is released later and this parallels TNF-a
which is released early while IFN-c which is released later
indicating that the expression of both chemokines and cytokines is
regulated [21]. Since CCL2 is released early we have focused on
the role of CCL2 in mycobacterial latent infection which is the
earliest consequence of susceptibility to infection.
In the current study, we show that the CCL-2 -2518 G
hi allele
was associated with an increased risk of latency, as this genotype
was overrepresented in the HC group compared to the community
controls and may contribute to increased genetic susceptibility in
the household contacts.
CCL-2 is a member of the small inducible gene (SIG) family
which is induced under conditions of oxidative stress, by cytokines
and or growth factors. CCL-2 chemokine is believed a play an
important role in both establishment and maintenance of
granuloma in latent infection as chemokine are pivotal in
recruitment of leukocytes to the site of infection [4]. A
polymorphism in the CCL-2 gene (-2518 A/T), differentially
controls the level of CCL-2 protein [5]. Several studies have
associated the G allele with increased expression of CCL-2 in
plasma [27] [28] [6] [29], other studies have reached the opposite
conclusion [30] [31] and some studies have failed to find a
significant difference in the plasma CCL-2 levels in individuals
harboring either allele [30]. In our study while plasma CCL-2
levels showed no relationship with CCL-2 genotype in the
asymptomatic controls (N=196; Kruskall-Wallis p=.454), a
significant difference in CCL-2 plasma levels was detected
between TST+ and TST2 donors in the asymptomatic group
which was most marked when the G allele was present. One likely
explanation may be the expression of specific Prep/Pbx proteins
complexes which regulate CCL-2 expression in different cells/
tissues during different infectious states [32].
The biological role of CCL-2 in tuberculosis has been addressed
in a previous study [6] where the investigators have shown that
stimulation of healthy monocytes from -2518GG with Mycobacte-
rium tuberculosis antigens yielded higher CCL-2 levels and lower IL-
12p40 compared with healthy -2518AA genotype. Therefore, the
investigators concluded that -2518 GG homozygote produce
higher concentrations of CCL-2 and suppress IL-12p40 produc-
tion responsible for deriving the IFN-c response. IFN- c is a key
macrophage activating cytokine and has been shown to be a
central molecule in protection against mycobacteria.
Furthermore, In vivo association studies of CCL-2 SNPs with
susceptibility to tuberculosis in different ethnic populations also
support the above observations. Flores -Villanueva et al found an
increased risk of developing tuberculosis in Mexicans and Koreans
heterozygous or homozygous for CCL-2 -2518G (rs1024611)
compared with those homozygous for -2518A allele [6]. ELISA
analysis showed that TB patients homozygous for -2518G had the
highest plasma levels of CCL-2 and the lowest plasma levels of
IL12p40, and these values were negatively correlated. Stimulation
of monocytes from healthy -2518G homozygotes with M.
tuberculosis antigens also yielded higher CCl-2 and lower IL12p40
compared with healthy -2518A homozygotes. Addition of anti-
CCL-2 antibodies increased IL12 production by -2518G homo-
zygotes, whereas addition of CCL-2 reduced IL12 production by -
2518A homozygotes. The investigators [6] concluded that those
with the CCL-2 -2518 GG genotype produce high concentration
of CCL-2, which inhibits IL12p40 production in response to M.
tuberculosis and increases the likelihood of TB infection progressing
to active disease. We have reported that IFN-c -874 T
hi allele was
associated with less severe pulmonary disease but not with severe
pulmonary or extra pulmonary tuberculosis [33] while CCL-2
responses show the opposite trend and are higher in severe disease
compared to less severe disease [23]. Increased levels of CCL2 in
TST+ donors in the current study are consistent with our previous
report of higher CCL2 in TST+ EC compared to TST2 EC [25]
and lower IFN-c levels in TST+ HC compared to TST+ EC [34].
CCL-2 acts predominantly on activated/memory stages of T
cells [35]. CCL-2 is the only chemokines which exerts chemotactic
effect on both Th1 and Th2 cells [36]. Furthermore CCL-2 is able
to polarize Th0 phenotype to Th2 phenotype by up regulating IL-
4 transcription thus indicating that CCL-2 may be part of the Th2
circuit [37]. The major purpose of granuloma is to create a focus
of inflammatory cells that prevents inflammation from occurring
systemically and maintaining a pro-inflammatory/anti-inflamma-
tory balance within the granuloma to reduce pathology. Excessive
levels of CCL-2 may however lead to increase risk of infection and
disease progression by virtue of its ability to activate the Th2
circuit. In TB endemic regions concomitant infections with
helminths can also skew the immune response towards Th2 and
may enhance CCL2 responses which forms part of the Th2 loop.
This study is set in a peri-urban area of Karachi, where the
incidence of helminth infections is relatively low and as such
should have little effect in skewing Th1/Th2 response. We have
not screened our healthy donors for common parasitic infections.
Nevertheless, all healthy donors were derived from the same socio-
economic strata and therefore, it is unlikely that the incidence of
parasitic infections will be different in TST2 and TST+ donors.
Paradoxically our results indicate higher plasma CCL2 responses
in TST+ (Th1 associated) donors rather than TST2 donors.
In conclusion we have identified an association of elevated
CCL-2 plasma levels with latent tuberculosis and a further effect of
GG genotype in increasing the risk of latent infection. This
association was irrespective of remote or recent infection. This is
not surprising as CCL-2 plays an important role in recruitment of
Table 4. Receiver Operator analysis of CCL2 (pg/ml) in
Healthy Asymptomatic Community Controls in relation to
Tuberculin Skin test Status (TST).
Groups N AUROC p= CI
EC2 Vs HC + 27 Vs 80 .736 0.0003 0.605–.867
EC2 VS HC 27 Vs 104 .694 0.002 .571–.817
EC+ Vs HC+ 24 Vs 80 .658 0.019 .172–.512
EC=Community Controls; HC exposed household contacts. +=TST positive
(.=10 mm indurations);
2=TST negative (,10 mm indurations).
doi:10.1371/journal.pone.0025803.t004
CCL2/MCP1 Is Elevated in Latent Tuberculosis
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e25803T memory cells to the site infection which are long lived in a BCG
vaccinated population [38]. Variable associations in different
ethnic population may be due to both variability in the prevalence
of latent infection, as well as variability of frequencies of the
different CCL-2 genotypes.
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